Immunic Execs to Fan Out Across July Investor Conferences
Event summary
- Immunic execs to attend three investor conferences in July, including Leerink Partners Therapeutics Forum (July 14-15), B. Riley Securities Mind, Muscle & Vision Summit (July 16), and LifeSci Capital SF Biotech Forum (July 23).
- CEO Erik Lundgren, President Jason Tardio, CMO Michael Panzara, and IR head Jessica Breu will participate in one-on-one investor meetings at all events.
- B. Riley summit includes a fireside chat with Lundgren, Tardio, and Panzara on July 16 at 1:30 pm ET.
- Immunic's lead program, vidofludimus calcium (IMU-838), in Phase 3 trials for relapsing multiple sclerosis, with top-line data expected by year-end.
The big picture
Immunic's aggressive investor outreach comes as it prepares for pivotal Phase 3 data that could determine its near-term valuation. The company is positioning itself as a leader in oral neurology treatments, but must prove its lead asset can compete with established therapies. These conferences provide a platform to showcase both clinical progress and pipeline potential to a broad audience of healthcare investors.
What we're watching
- Clinical Milestones
- Whether Immunic can maintain momentum ahead of Phase 3 data readout for IMU-838 by year-end.
- Investor Sentiment
- How conference presentations impact investor perception of Immunic's pipeline beyond multiple sclerosis.
- Competitive Positioning
- The pace at which Immunic can differentiate its oral therapies in the crowded neuroinflammatory disease space.
Related topics